Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced the publication of final efficacy results from their Phase 3 trial of the COVID-19 vaccine candidate BNT162b2. Involving 43,448 participants aged 16 and older, the trial demonstrated a 95% efficacy rate against COVID-19 with a favorable safety profile. The trial results showed that the vaccine was well-tolerated across diverse populations, including those with pre-existing conditions. The companies are pursuing regulatory submissions globally, having received emergency use authorizations in several countries.
Pfizer and BioNTech have released pivotal Phase 3 trial results for BNT162b2, their mRNA-based COVID-19 vaccine, published in the New England Journal of Medicine. The trial involved 43,448 participants and showed a remarkable 95% efficacy in preventing COVID-19 after a two-dose regimen. The vaccine was well-tolerated, with common side effects like fatigue and pain at the injection site. The companies are seeking Emergency Use Authorization from the FDA and have already received approvals in other countries. Ongoing monitoring for long-term safety and efficacy will continue for two more years.
Pfizer Inc. (NYSE:PFE) announced the FDA's acceptance for priority review of its Biologics License Application (BLA) for the 20-valent pneumococcal conjugate vaccine (20vPnC). This vaccine aims to prevent invasive diseases and pneumonia in adults aged 18 and older caused by multiple Streptococcus pneumoniae serotypes. The FDA decision is expected by June 2021. The 20vPnC vaccine shows promise in inducing immune memory and covers more serotypes than any currently licensed vaccine, potentially addressing a significant public health issue as pneumococcal pneumonia results in an estimated 500,000 deaths annually worldwide.
PostEra has formed a strategic partnership with Pfizer Inc. (NYSE: PFE), focusing on enhancing small molecule drug discovery through advanced machine learning technologies. This multi-year collaboration aims to develop a generative chemistry platform to optimize novel molecular structures.
PostEra will receive upfront payments and additional funding as the project progresses while retaining rights to all developed algorithms. Both companies will combine Pfizer's extensive data and PostEra's technological capabilities to address challenges in preclinical drug discovery.
Pfizer Inc. (NYSE:PFE) has released promising safety and clinical response results from its Phase 1 study of PF-06863135, a bispecific antibody targeting B-cell maturation antigen (BCMA) for treating relapsed or refractory multiple myeloma. Involving 30 patients, the study showed no dose-limiting toxicities and an 83% clinical response rate at the highest dose level of 1,000 μg/kg. Cytokine release syndrome was reported but primarily mild. The data suggests PF-06863135 could be a significant advancement in multiple myeloma treatment, supporting its further development.
Pfizer (NYSE: PFE) and Sangamo Therapeutics have shared updated data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy for severe hemophilia A, presented at the 62nd American Society for Hematology Annual meeting. The study’s high-dose cohort (3 x 1013 vg/kg) showed sustained factor VIII activity for over a year, with a median FVIII activity of 56.9% and no bleeding events during the first year. Adverse events were minor, and the therapy was generally well tolerated. A pivotal Phase 3 study is underway, with results expected by 2022.
Pfizer and BioNTech announced that the U.K.'s MHRA has granted a temporary Emergency Use Authorization for their COVID-19 mRNA vaccine, BNT162b2. This is a historic milestone as it is the first such authorization following a global Phase 3 trial showing a 95% efficacy rate. The companies plan to deliver up to 40 million doses, prioritizing high-risk populations as per U.K. guidelines. The regulatory review is ongoing in other regions, including the U.S. and EU, with Pfizer's extensive distribution capabilities expected to facilitate rapid vaccine rollout globally.
Pfizer Inc. (NYSE: PFE) has initiated the Phase 3 BASIS study for marstacimab (PF-06741086), aimed at treating severe hemophilia A or B. This multicenter trial will assess annualized bleed rate (ABR) over 12 months among participants undergoing prophylactic treatment. Previous Phase 2 results indicated a significant reduction in ABR (>75%) and no serious adverse events. Marstacimab could potentially eliminate the need for factor replacement therapy, offering a novel subcutaneous treatment option for patients.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced their request for Emergency Use Authorization (EUA) of the mRNA vaccine candidate BNT162b2 against SARS-CoV-2. The vaccine demonstrated 95% efficacy in Phase 3 trials, involving over 43,000 participants. Safety data shows no serious concerns. If authorized, the companies can distribute 50 million doses globally in 2020 and 1.3 billion by the end of 2021. The collaboration aims to facilitate rapid global vaccine distribution amidst rising COVID-19 cases.
Pfizer Inc. (NYSE:PFE) announced significant results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib) versus XALKORI® (crizotinib) for previously untreated ALK-positive advanced non-small cell lung cancer (NSCLC). LORBRENA showed a statistically significant improvement in progression-free survival (PFS) with a 72% risk reduction of progression or death (HR 0.28, p<0.001). Furthermore, the objective response rate was 76% for LORBRENA versus 58% for XALKORI. These findings will be reviewed under the FDA's Real-Time Oncology Review pilot program for potential first-line indication.